EULAV Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

EULAV Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.69M	Sell	19,500 -1,500	-7%	-$665K	0.31%	86
2026 Q1	$9.38M	Sell	21,000 -1,000	-5%	-$466K	0.3%	88
2025 Q4	$9.97M	Hold	22,000	–	–	0.27%	100
2025 Q3	$8.62M	Sell	22,000 -700	-3%	-$293K	0.2%	108
2025 Q2	$10.1M	Sell	22,700 -5,800	-20%	-$2.67M	0.24%	98
2025 Q1	$13.8M	Hold	28,500	–	–	0.34%	77
2024 Q4	$11.5M	Sell	28,500 -3,000	-10%	-$1.39M	0.28%	90
2024 Q3	$14.7M	Sell	31,500 -4,500	-13%	-$2.16M	0.36%	77
2024 Q2	$16.9M	Sell	36,000 -1,900	-5%	-$825K	0.46%	62
2024 Q1	$15.8M	Sell	37,900 -500	-1%	-$211K	0.44%	64
2023 Q4	$15.6M	Buy	38,400 +5,000	+15%	+$1.85M	0.48%	59
2023 Q3	$11.6M	Sell	33,400 -2,100	-6%	-$734K	0.42%	71
2023 Q2	$12.5M	Sell	35,500 -2,000	-5%	-$674K	0.47%	62
2023 Q1	$11.8M	Sell	37,500 -4,500	-11%	-$1.35M	0.47%	62
2022 Q4	$12.1M	Sell	42,000 -6,010	-13%	-$1.83M	0.52%	58
2022 Q3	$13.9M	Sell	48,010 -5,998	-11%	-$1.73M	0.62%	57
2022 Q2	$15.2M	Sell	54,008 -5,999	-10%	-$1.61M	0.63%	56
2022 Q1	$15.7M	Sell	60,007 -19,993	-25%	-$4.74M	0.47%	66
2021 Q4	$17.6M	Sell	80,000 -28,000	-26%	-$5.44M	0.44%	73
2021 Q3	$19.6M	Sell	108,000 -34,000	-24%	-$6.64M	0.52%	67
2021 Q2	$28.6M	Sell	142,000 -8,000	-5%	-$1.67M	0.76%	45
2021 Q1	$32.2M	Buy	150,000 +72,000	+92%	+$15.8M	0.86%	38
2020 Q4	$18.4M	Buy	78,000 +31,500	+68%	+$7.23M	0.48%	76
2020 Q3	$12.7M	Sell	46,500 -20	-0%	-$5.52K	0.37%	91
2020 Q2	$13.5M	Sell	46,520 -4,480	-9%	-$1.21M	0.44%	77
2020 Q1	$12.1M	Sell	51,000 -7,000	-12%	-$1.61M	0.49%	71
2019 Q4	$12.7M	Sell	58,000 -11,000	-16%	-$2.23M	0.44%	78
2019 Q3	$11.7M	Sell	69,000 -3,000	-4%	-$531K	0.43%	77
2019 Q2	$13.2M	Hold	72,000	–	–	0.5%	65
2019 Q1	$13.4M	Sell	72,000 -7,000	-9%	-$1.29M	0.55%	60
2018 Q4	$13.1M	Sell	79,000 -16,000	-17%	-$2.77M	0.65%	51
2018 Q3	$18.3M	Sell	95,000 -12,000	-11%	-$2.14M	0.78%	36
2018 Q2	$18.2M	Sell	107,000 -10,000	-9%	-$1.55M	0.84%	33
2018 Q1	$19.1M	Sell	117,000 -16,000	-12%	-$2.61M	0.91%	27
2017 Q4	$19.9M	Buy	133,000 +8,000	+6%	+$1.18M	0.94%	24
2017 Q3	$19M	Sell	125,000 -4,000	-3%	-$602K	0.9%	28
2017 Q2	$16.6M	Sell	129,000 -8,000	-6%	-$963K	0.81%	32
2017 Q1	$15M	Sell	137,000 -5,000	-4%	-$440K	0.76%	37
2016 Q4	$10.5M	Sell	142,000 -6,000	-4%	-$488K	0.56%	60
2016 Q3	$12.9M	Buy	148,000 +12,000	+9%	+$1.13M	0.68%	44
2016 Q2	$11.7M	Sell	136,000 -10,000	-7%	-$864K	0.64%	51
2016 Q1	$11.6M	Buy	146,000 +25,000	+21%	+$2.26M	0.65%	53
2015 Q4	$15.2M	Sell	121,000 -1,000	-0.8%	-$121K	0.83%	32
2015 Q3	$12.7M	Buy	122,000 +96,000	+369%	+$12.3M	0.72%	40
2015 Q2	$3.21M	Buy	+26,000	New	+$3.28M	0.17%	180

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

EULAV Asset Management's VRTX Position: Q2 2026 in Review

EULAV Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 7.1% in Q2 2026, selling an estimated $665K and leaving 19,500 shares worth $9.69M. The position accounts for 0.31% of the portfolio, ranked #86.

EULAV Asset Management first reported a position in VRTX in Q2 2015 and has held it in 45 quarters since. The position peaked at $32.2M in Q1 2021. 685 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

EULAV Asset Management held 19,500 shares of Vertex Pharmaceuticals worth $9.69M as of Q2 2026.
EULAV Asset Management sold 1,500 Vertex Pharmaceuticals shares in Q2 2026, an estimated $665K.
Vertex Pharmaceuticals made up 0.31% of EULAV Asset Management's portfolio in Q2 2026, its #86 holding.
EULAV Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2015 and has held it in 45 quarters since.
EULAV Asset Management's Vertex Pharmaceuticals position peaked at $32.2M in Q1 2021.
685 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on EULAV Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.